261 related articles for article (PubMed ID: 31909761)
1. [Immunotherapy in non-small cell lung cancer patients: back to the future.].
Roberto M; Botticelli A; Cecere F; Cognetti F; Giusti R; Gelibter A; Lugini A; Nelli F; Nuti M; Santini D; Marchetti P
Recenti Prog Med; 2019 Dec; 110(12):587-593. PubMed ID: 31909761
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
5. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
Cetin B; Bilgetekin İ; Ozet A
Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
7. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
9. [Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.].
Fasola G; De Carlo E; Grossi F
Recenti Prog Med; 2018 Jun; 109(6):328-332. PubMed ID: 29968861
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
11. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Qiao M; Jiang T; Ren S; Zhou C
Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
13. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
14. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
[TBL] [Abstract][Full Text] [Related]
17. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
18. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents.
Puri S; Chatwal M; Gray JE
Expert Rev Respir Med; 2017 Oct; 11(10):791-805. PubMed ID: 28786318
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
Rolfo C; Sortino G; Smits E; Passiglia F; Bronte G; Castiglia M; Russo A; Santos ES; Janssens A; Pauwels P; Raez L
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1173-87. PubMed ID: 25148289
[TBL] [Abstract][Full Text] [Related]
20. Treatment options after first-line immunotherapy in metastatic NSCLC.
Santos ES
Expert Rev Anticancer Ther; 2020 Mar; 20(3):221-228. PubMed ID: 32141356
[No Abstract] [Full Text] [Related]
[Next] [New Search]
